Restoration of Tight-Junction Function: A New Therapeutic Approach for the Treatment of Cancer

Shah, Girish V.

doi:10.4172/2167-0501.1000e130

Search citation statements

Order By: Relevance

Paper Sections

Select...

Therapeutic Approaches and Caveats1

Outlook-inhibiting Cancer Cell Proliferation By Stabilising ...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the ECM and TJs have gained more interest as therapeutic targets in cancer and MS [110][111][112][113][114]. Targeting of the cell-ECM interface was successfully done in cancer because abnormal expression of integrins and their ECM ligands promotes cell proliferation, migration, and differentiation [113].…”

Section: Therapeutic Approaches and Caveatsmentioning

confidence: 99%

Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders

Demeestere

Libert

Vandenbroucke

2015

Drug Discovery Today

View full text Add to dashboard Cite

Section: Therapeutic Approaches and Caveatsmentioning

confidence: 99%

Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders

Demeestere

Libert

Vandenbroucke

2015

Drug Discovery Today

View full text Add to dashboard Cite

“…TJ loss has been established in a myriad of cancers (Salvador et al, 2016) and leads to the activation of many downstream signalling pathways (Bhat et al, 2019). Although this makes the TJ an interesting target in cancer treatment (Shah, 2012), a current lack of understanding of how different TJ components are involved in regulating these pathways in cancer poses a barrier to investigating TJ proteins specifically as therapeutic targets (Bhat et al, 2019).…”

Section: Outlook-inhibiting Cancer Cell Proliferation By Stabilising ...mentioning

confidence: 99%

The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype

Tucker

Zorn

2021

British J Pharmacology

View full text Add to dashboard Cite

The Popeye domain-containing protein 1 (POPDC1), a tight junction-associated transmembrane protein with a unique binding site for cAMP, has been shown to act as a tumour suppressor in cancer cells. Through interaction with many downstream effectors and signalling pathways, POPDC1 promotes cell adhesion and inhibits uncontrolled cell proliferation, epithelial-to-mesenchymal transition and metastasis.However, POPDC1 expression is down-regulated in many types of cancer, thereby reducing its tumour-suppressive actions. This review discusses the role of POPDC1 in the progression of the malignant phenotype and highlights the broad range of benefits POPDC1 stabilisation may achieve therapeutically. Cancer stem cells (CSCs) are a key hallmark of malignancies and commonly promote treatment resistance. This article provides a comprehensive overview of CSC signalling mechanisms, many of which have been shown to be regulated by POPDC1 in other cell types, thus suggesting an additional therapeutic benefit for POPDC1-stabilising anti-cancer drugs.

show abstract

Restoration of Tight-Junction Function: A New Therapeutic Approach for the Treatment of Cancer

Cited by 2 publications

References 24 publications

Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders

Clinical implications of leukocyte infiltration at the choroid plexus in (neuro)inflammatory disorders

The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype

Contact Info

Product

Resources

About